# A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity

> **NCT05236517** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 60 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Semaglutide D Dose 1
- **DRUG:** Semaglutide D Dose 2
- **DRUG:** Semaglutide D Dose 3
- **DRUG:** Semaglutide C Dose 4
- **DRUG:** Semaglutide C Dose 5 (50 mg)
- **DRUG:** Placebo (Semaglutide C)
- **DRUG:** Placebo ( Semaglutide D)

## Key facts

- **NCT ID:** NCT05236517
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-08
- **Primary completion:** 2022-09-29
- **Final completion:** 2022-11-07
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05236517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05236517, "A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05236517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*